Journal of Personalized Medicine · 6 authors, 4 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
This retrospective study analyzed adverse drug reactions in 47 patients with multidrug-resistant tuberculosis treated with amikacin and/or capreomycin. The central result was that ototoxicity was significantly more common in patients who received amikacin, while nephrotoxicity was associated with pre-existing renal impairment, and no specific mitochondrial DNA variants were linked to these adverse events.
This retrospective study evaluated 47 Latvian patients with multidrug-resistant tuberculosis who received amikacin and/or capreomycin to analyze the occurrence of adverse drug reactions, specifically ototoxicity and nephrotoxicity. Researchers also explored the role of various factors, including genetic analysis via full mitochondrial genome sequencing. The central results showed that 16 patients (34.0%) developed ototoxicity and 13 patients (27.7%) developed nephrotoxicity. Ototoxicity was significantly more common in patients who received amikacin. Nephrotoxicity was more frequent in older patients and was likely associated with previous renal health impairment. Full mitochondrial genome sequencing did not reveal any specific variants associated with the adverse events, and no differences were found for mutation count or mitochondrial haplogroup. The study's primary limitations were the small cohort size and retrospective design, which may obscure the impact of individual variability on adverse event risk. The findings suggest that the occurrence of these adverse events is complex and not solely explained by the tested genetic factors.
